MDPI and ACS Style
El-Sherbiny, M.; El-Shafey, M.; Said, E.; Shaker, G.A.; El-Dosoky, M.; Ebrahim, H.A.; Abed, S.Y.; Ibraheem, K.M.; Mohsen Faheem, A.; AlMutawa, M.;
et al. Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation. Life 2022, 12, 764.
https://doi.org/10.3390/life12050764
AMA Style
El-Sherbiny M, El-Shafey M, Said E, Shaker GA, El-Dosoky M, Ebrahim HA, Abed SY, Ibraheem KM, Mohsen Faheem A, AlMutawa M,
et al. Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation. Life. 2022; 12(5):764.
https://doi.org/10.3390/life12050764
Chicago/Turabian Style
El-Sherbiny, Mohamed, Mohamed El-Shafey, Eman Said, Gehan Ahmed Shaker, Mohamed El-Dosoky, Hasnaa Ali Ebrahim, Sally Yussef Abed, Khalid M. Ibraheem, Ahmed Mohsen Faheem, Muntazar AlMutawa,
and et al. 2022. "Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury—Insight into Oxidative Injury/Inflammation/Apoptosis Modulation" Life 12, no. 5: 764.
https://doi.org/10.3390/life12050764